Precision Antimicrobials Against Drug-Resistant Bacteria

Introduction: Why Therapeutic Phages Matter

The world is facing a microbial crisis unlike any in modern medicine. Antibiotic resistance has transformed once-manageable infections into life-threatening conditions, with the WHO, CDC, and EMA consistently ranking antimicrobial resistance (AMR) among the top global health threats. Traditional small-molecule antibiotics are failing at an alarming rate, and the pipeline of new compounds has slowed to a trickle. Against this backdrop, phage therapeutics—viruses that infect and lyse bacteria—are emerging as a revolutionary countermeasure.

At Phage Biologics, we exist for one reason: to bring phage therapeutics from concept to clinic. Unlike broad-spectrum antibiotics, bacteriophages are highly specific, precision antimicrobials capable of targeting and destroying pathogenic bacteria without disturbing commensal flora. Their inherent ability to co-evolve with bacterial resistance mechanisms makes them uniquely suited for long-term deployment in infectious disease management.

Where most CDMOs offer phage services as an afterthought, we are the first CDMO specialized exclusively in therapeutic phages. That singularity of focus allows us to deliver unmatched expertise — from phage discovery and process development to GMP manufacturing — tailored specifically to the challenges of developing safe, potent, and regulatory-compliant phage-based medicines.

This page outlines our comprehensive services for therapeutic phages, structured across the development continuum: strain selection, phage amplification, fermentation and purification, analytics, regulatory alignment, and GMP-readiness. Whether you are an early-stage biotech validating a therapeutic concept, or a global pharmaceutical company preparing for multi-center trials, Phage Biologics offers the specialized capabilities you need.

Strain Selection & Phage Discovery

Developing therapeutic phages begins with the right host and the right viral arsenal.

Our CDMO Capabilities

• Clinical Isolate Libraries – We maintain curated collections of pathogenic clinical isolates, including Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, and multi-drug resistant E. coli.
• High-Throughput Screening – Robotic platforms enable rapid plaque assays across hundreds of phage-host combinations, identifying candidate lytic phages with optimal host range and potency.
• Genomic Characterization – Whole-genome sequencing (WGS) and bioinformatics pipelines ensure therapeutic phages are devoid of lysogeny-associated genes, toxin-encoding elements, or antibiotic resistance cassettes.
• Custom Strain Incorporation – Clients can supply proprietary bacterial isolates; we integrate them seamlessly into our workflow to ensure relevance to intended clinical targets.

Why This Matters

The success of a therapeutic phage hinges on early decisions in strain selection and genetic vetting. Our integrated approach reduces the risk of late-stage attrition by ensuring only the most robust, lytic, and safe candidates progress downstream.

Phage Amplification & Fermentation

Amplifying phages at scale is not trivial—it demands deep microbial process expertise, scalable infrastructure, and precise control.

Pilot-Scale Amplification

• Bioreactors from 2L to 50L – Ideal for research-grade batches and process development.
• Optimized Host Preparation – Defined media and fed-batch fermentation maximize bacterial host density, providing high-yield phage amplification platforms.

GMP-Scale Manufacturing

• 100L to 2000L Fermentation Systems – State-of-the-art stainless steel and single-use bioreactors enable scalability from Phase I to commercial supply.
• Infection Dynamics Control – Real-time monitoring of optical density, multiplicity of infection (MOI), and lysis kinetics ensures consistent phage titers and infectivity.
• Cold-Shock & Process Timing – Minimization of degradation pathways through rapid harvest protocols designed to preserve phage integrity.

Why This Matters

Phage amplification requires balancing biology (bacterial growth kinetics, host cell lysis) with engineering (bioreactor control, aseptic sampling). Our precision-controlled systems ensure reproducibility, scalability, and regulatory alignment.

Downstream Purification

Phages must be purified to remove host cell debris, endotoxins, and residual bacterial nucleic acids.

Purification Strategies

• Clarification – Tangential flow filtration (TFF) and depth filtration eliminate cell debris without compromising phage infectivity.
• Concentration & Buffer Exchange – Ultrafiltration modules concentrate high-titer phages into clinical-grade formulations.
• Endotoxin Removal – Proprietary chromatography workflows reduce endotoxin levels below stringent FDA and EMA thresholds.
• Nuclease Treatment – Enzymatic degradation removes residual bacterial DNA, ensuring genomic purity.

GMP Validation

• All purification workflows are validated for clearance of critical impurities, documented with batch records and SOP alignment to regulatory expectations.

Why This Matters

Endotoxin and DNA impurities are major regulatory hurdles for therapeutic phages. Our advanced purification platforms achieve clearance levels that withstand the highest global scrutiny.

QC & Analytics

Robust quality control is the backbone of therapeutic phage development.

Assays We Offer

• Potency Assays – Plaque-forming unit (PFU) counts, one-step growth curves, and burst size determination.
• Genetic Identity – qPCR and digital PCR (ddPCR) confirming phage genome integrity and quantifying viral load.
• Stability Studies – Accelerated degradation, freeze-thaw cycles, and long-term storage monitoring to establish shelf life.
• Infectivity Assays – Multi-host panel screening ensures retention of therapeutic activity across relevant bacterial strains.
• Safety Testing – Endotoxin (LAL assays), sterility, mycoplasma, and adventitious agent testing per ICH/FDA guidelines.

Why This Matters

For phages to gain regulatory and clinical acceptance, sponsors must provide bulletproof analytical datasets. Our QC platform delivers this confidence—empowering you to advance through IND and IMPD milestones.

Regulatory Alignment

Phage therapy development requires navigating a patchwork of evolving regulatory frameworks.

Our Expertise

Regulatory Alignment & Global Strategy

• FDA & EMA Guidelines – Our processes are built in strict alignment with current FDA and EMA positions on phage therapy, including evolving guidance on compassionate use, expanded access, and formal IND/IMPD pathways. By embedding compliance into development, we reduce regulatory risk and accelerate the approval timeline.
• CMC Support – We provide full Chemistry, Manufacturing, and Controls (CMC) documentation to support submissions, covering process descriptions, control strategies, validation data, and stability programs. This ensures INDs, IMPDs, and CTA dossiers are submission-ready with minimal iteration.
• Comparability Studies – We design and execute comparability protocols to demonstrate product consistency across scales, sites, and process variations — a non-negotiable expectation for biologics and essential for global approvals.
• Global Readiness – Regulatory strategies extend beyond FDA and EMA to include Health Canada, ANSM (France), and MHRA (UK), ensuring your phage therapy program is aligned with multinational trial requirements and ready for global commercialization.
• Regulatory Intelligence – Continuous monitoring of agency positions allows us to anticipate shifts in phage regulation and adapt client strategies proactively.

Why This Matters

Phage therapy has entered mainstream clinical development, but regulatory frameworks are still evolving. Our regulatory expertise provides an early compliance advantage, reducing the risk of costly delays, incomplete submissions, or failed reviews.

GMP-Readiness & Clinical Supply

From lab bench to bedside, phages must be manufactured under conditions that satisfy regulators, clinicians, and patients alike. Unlike platforms retrofitted from antibody or protein biologics, our infrastructure is purpose-built for phages.

GMP Capabilities

• ISO-Classified Cleanrooms – Controlled environments designed specifically for viral biologics, compliant with ISO 7/ISO 5 standards for aseptic processing.
• Batch Records & Traceability – End-to-end documentation systems, including electronic batch records (EBR), real-time monitoring, and complete audit trails, ensuring full data integrity.
• QA/QC Oversight – Quality is embedded at every stage with real-time review, in-process controls, and qualified release functions. Our QC labs include qPCR, infectivity assays, electron microscopy, and endotoxin validation.
• Sterile Fill–Finish – Single-use technologies and Grade A isolators ensure aseptic vialing and syringe filling, with validated container–closure integrity and stability programs.
• Environmental Monitoring – Continuous systems for microbial load, particulates, and cleanroom performance, ensuring ongoing GMP compliance.

Why This Matters

Therapeutic phages require bespoke GMP frameworks. By building GMP systems specifically for phages — rather than adapting protein biologics infrastructure — we minimize contamination risk, optimize yields, and accelerate clinical readiness.

Integrated Development Continuum

What makes Phage Biologics unique is not simply the breadth of our individual services, but the way they interlock into a seamless continuum. In most CDMOs, workflows are fragmented across multiple vendors, creating bottlenecks, data loss, and regulatory gaps. Our approach is different: every stage informs the next, ensuring alignment, continuity, and acceleration.

Discovery → Development → GMP, all under one roof.

• Risk Reduction – Because we focus exclusively on phage therapeutics, every workflow has been engineered for the biology, stability, and scalability of bacteriophages. By eliminating the need for generalist CDMOs, we reduce contamination risks, process deviations, and costly delays.
• Customization – We provide modular service packages designed to meet your program at the right stage. From exploratory strain screening and proof-of-concept studies to late-phase GMP production of phage therapeutics, our continuum adapts to your needs without compromising quality.
• Process Knowledge Transfer – Internal continuity ensures that process knowledge flows forward without loss. Data integrity is preserved across discovery, process development, and GMP, allowing for smoother tech transfer and minimizing the risk of comparability failures.
• Acceleration – An integrated model means fewer bottlenecks, shorter timelines, and reduced costs. With our specialized focus on phage therapeutics, timelines can be compressed while still maintaining the rigor required for regulatory approval.

In short, our continuum eliminates the inefficiencies of fragmented outsourcing and provides a purpose-built pipeline for phage therapeutics, from early concept through global clinical deployment.

Why Choose Phage Biologics

• Niche Focus – Unlike broad-spectrum CDMOs, we exist exclusively for therapeutic phages and phage therapeutics, ensuring unparalleled specialization and technical insight.
• Deep Expertise – Our team brings decades of combined experience in phage biology, fermentation optimization, analytical method development, and regulatory science tailored specifically to phage-based medicines.
• Scalable Infrastructure – Flexible capacity ranging from small-scale pilot fermentation to full GMP commercial production, all purpose-built for phage-specific workflows.
• Global Regulatory Alignment – Prepared for FDA, EMA, Health Canada, MHRA, and ANSM submissions, with strategies tailored to the evolving regulatory frameworks governing phage therapeutics worldwide.
• Client-Centric Partnerships – Agile, collaborative, and transparent, we function as an extension of your R&D team — integrating scientific insight with operational excellence to accelerate progress.

At Phage Biologics, we don’t just provide services — we provide confidence. By combining deep technical infrastructure, global regulatory foresight, and a singular focus on phages, we give innovators the tools to advance their phage therapeutics programs efficiently, compliantly, and globally.

Building the Future of Anti-Infectives

The world cannot afford to wait for new antibiotics to trickle through development pipelines while antimicrobial resistance (AMR) escalates at an alarming pace. Phage therapeutics are no longer a theoretical alternative — they represent a critical necessity in the future of infectious disease management.

At Phage Biologics, we are proud to be the first CDMO dedicated exclusively to therapeutic phages. Every facility, every cleanroom, and every SOP has been designed with the biology, safety, and scalability of phage therapy in mind. This singular focus makes us the partner of choice for biotechs and pharmaceutical companies determined to transform the promise of phage therapeutics into reality.

From strain selection and amplification, through purification, quality control, and analytical validation, to GMP manufacturing and regulatory documentation, our platform delivers precision antimicrobials against drug-resistant pathogens — at scale, with compliance, and with speed.

Together, we can move beyond the waning age of antibiotics into a new era defined by phage therapeutics — precision antimicrobials built for the future of medicine.

Contact our team at info@phagebiologics.com